Clinical trial cost per patient was highest in the blood therapeutic area, ranging between 200 thousand and 422 thousand U.S. dollars with a median of some 311 thousand dollars. This statistic shows the estimated per patient trial costs by therapeutic area, for the period 2015-2017.

This statistic shows the estimated average per-patient biopharmaceutical clinical trial costs in the United States in 2013, by selected condition. In that year the cost per patient for clinical trials for new medicines related to oncology were estimated to be around 59,500 dollars.

This statistic shows the estimated per drug trial costs by therapeutic area, for the period 2015-2017. Clinical trial cost per drug was the highest for cardiovascular drugs, ranging between 74 million and 183 million U.S. dollars with a median of 141 million dollars.

Dermatology CRO Market size was valued at USD 4.91 Billion in 2024 and is projected to reach USD 8.32 Billion by 2031, growing at a CAGR of 6.80% during the forecast period 2024-2031.

Global Dermatology CRO Market Drivers

The market drivers for the Dermatology CRO Market can be influenced by various factors. These may include:

Growing Prevalence of Skin Disorders: The need for dermatological services, including clinical trials, is being driven by the increased prevalence of a number of skin conditions, including eczema, psoriasis, acne, and skin cancer.
Growing Need for Cosmetic Procedures: As people attention turns more and more to appearances, there is a greater need for cosmetic dermatological treatments. This, in turn, raises the question of whether clinical research is necessary in this area.
Developments in Dermatological medicines: The demand for clinical trials to evaluate the safety and efficacy of dermatological medicines, such as biologics, targeted therapies, and personalized medicine, is growing.
Growing R&D Investments: More clinical trials and partnerships with CROs are being conducted as a result of pharmaceutical and biotechnology companies’ growing R&D expenditures in dermatology.
Regulatory encourage for Clinical Research: The dermatology CRO industry is expanding as a result of favorable regulatory policies and programs that encourage clinical research. Examples of these include accelerated approval processes and incentives for research on rare diseases.
Technological Advancements in Clinical studies: More sponsors are choosing to undertake dermatology studies as a result of the increased efficiency, lower costs, and increased use of technology like as wearables, telemedicine, and electronic data capture (EDC).
Increasing Trend of R&D Activity Outsourcing: As sponsors may concentrate on their core skills and cut research expenses, there is an increasing trend of outsourcing R&D operations, including clinical trials, to CROs.

Snapshot img

Clinical Trial Imaging Market Size 2024-2028

The clinical trial imaging market size is forecast to increase by USD 551.3 million at a CAGR of 7.5% between 2023 and 2028.

The market is experiencing significant growth due to the increasing investment in drug development for chronic diseases. Imaging techniques, such as Computed Tomography (CT), play a crucial role in clinical trials by providing valuable data for drug efficacy and safety assessments. Patient comfort is a key trend in this market, as Breast imaging technologies are being developed to minimize patient discomfort and improve the overall trial experience. Data management services are also gaining importance to ensure accurate and efficient handling of imaging data. Strict regulations, however, pose a challenge to market growth, requiring strong data security and compliance measures. Overall, the market is expected to continue its expansion, driven by the need for advanced imaging technologies to support the development of new treatments.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The integration of medical imaging technologies in clinical trials has revolutionized the biotechnology and pharmaceutical industries. By providing valuable insights into various health conditions, these advanced imaging techniques contribute significantly to the development of new therapeutics and treatments. In the realm of clinical trials, imaging technologies play a pivotal role in assessing the efficacy and safety of new drugs and therapies. Biotechnology and pharmaceutical companies increasingly rely on these technologies to gather data on disease progression, treatment response, and potential side effects. Image analysis software, fueled by artificial intelligence (AI) and machine learning algorithms, is a crucial component of this process. 



These advanced technologies enable the automated detection, measurement, and analysis of various health conditions, including oncology, non-alcoholic steatohepatitis (NASH), neurology, endocrinology, and cardiology. Virtual imaging trials, which utilize AI and machine learning, have gained considerable attention in recent years. These trials allow for remote patient monitoring and data collection, streamlining the clinical trial process and reducing costs. Imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), echocardiography, nuclear medicine (positron emission tomography – PET), x-ray, ultrasound, and optical coherence tomography, are essential tools in the clinical trial landscape.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Modality

  Computed tomography
  Magnetic resonance imaging
  Ultrasound
  Positron emission tomography
  Others


End-user

  Contract research organization
  Pharmaceutical and biotechnology companies
  Research and academic institutes
  Medical device manufacturers


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Modality Insights

The computed tomography segment is estimated to witness significant growth during the forecast period.

The market is experiencing notable progressions, with a notable focus on the computed tomography (CT) segment. CT imaging is a vital imaging modality in clinical trials due to its ability to generate detailed cross-sectional images of the body, which are crucial for precise diagnosis and tracking of various medical conditions, including cancer. The rising prevalence of chronic diseases and the demand for early and precise diagnosis have boosted the importance of high-resolution imaging technologies. CT scans are indispensable in evaluating disease progression and treatment effectiveness in clinical trials.

Furthermore, technological innovations in CT imaging, such as photon counting computed tomography (PCCT), are expanding the capabilities of clinical trial imaging. Magnetic Resonance Imaging (MRI), Echocardiography, Nuclear Medicine, Positron Emission Tomography (PET), and X-ray are other significant imaging modalities in clinical trials. MRI offers superior soft tissue contrast and is widely used in neurology, oncology, and cardiology trials. Hence, such factors are fuelling the growth of this segment during the forecast period.

Get a glance at the market report of share of various segments Request Free Sample

The computed tomography segment was valued at USD 317.40 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 38% to the growth of the global market during the

Healthcare Contract Research Outsourcing Market size was valued at USD 43.22 Billion in 2024 and is projected to reach USD 75.66 Billion by 2031, growing at a CAGR of 7.25% during the forecast period 2024-2031.

Global Healthcare Contract Research Outsourcing Market Drivers

The market drivers for the Healthcare Contract Research Outsourcing Market can be influenced by various factors. These may include:

Increasing Research and Clinical Trial Involvement: There has been an increase in research and development activity in the biotechnology and pharmaceutical sectors, which has raised the need for clinical trial outsourcing. Healthcare CROs are essential to the success of these trials and the expansion of the market as a whole.

Time savings and cost effectiveness: Drug development can proceed more quickly and with lower operating expenses for pharmaceutical and biotech businesses that outsource their clinical research operations to CROs. CROs frequently have specialized infrastructure and knowledge, which boosts productivity and shortens turnaround times.

Global Clinical Trials Industry: The increasing number of clinical trials being done in different parts of the world has led to the demand for CROs with local knowledge who can manage a variety of trial populations and negotiate regulatory environments.

The intricacy of the drug development process: With developments in personalized medicine, genetics, and medical research, the process of developing new drugs has grown increasingly intricate. To take use of CROs’ specialized resources and skills, pharmaceutical corporations outsource different parts of clinical trials to them.

Strategic Emphasis on Fundamental Skills: Many biotech and pharmaceutical businesses would rather outsource their clinical research operations to specialized CROs and concentrate on their core skills, such marketing and drug discovery. They are able to distribute resources more skillfully as a result.

ObjectiveOne key aspect of cancer survivorship is return-to-work. Unfortunately, many cancer survivors face problems upon their return-to-work. For that reason, we developed a hospital-based work support intervention aimed at enhancing return-to-work. We studied effectiveness of the intervention compared to usual care for female cancer patients in a multi-centre randomised controlled trial.MethodsBreast and gynaecological cancer patients who were treated with curative intent and had paid work were randomised to the intervention group (n = 65) or control group (n = 68). The intervention involved patient education and support at the hospital and improvement of communication between treating and occupational physicians. In addition, we asked patient's occupational physician to organise a meeting with the patient and the supervisor to make a concrete gradual return-to-work plan. Outcomes at 12 months of follow-up included rate and time until return-to-work (full or partial), quality of life, work ability, work functioning, and lost productivity costs. Time until return-to-work was analyzed with Kaplan-Meier survival analysis.ResultsReturn-to-work rates were 86% and 83% (p = 0.6) for the intervention group and control group when excluding 8 patients who died or with a life expectancy of months at follow-up. Median time from initial sick leave to partial return-to-work was 194 days (range 14–435) versus 192 days (range 82–465) (p = 0.90) with a hazard ratio of 1.03 (95% CI 0.64–1.6). Quality of life and work ability improved statistically over time but did not differ statistically between groups. Work functioning and costs did not differ statistically between groups.ConclusionThe intervention was easily implemented into usual psycho-oncological care and showed high return-to-work rates. We failed to show any differences between groups on return-to-work outcomes and quality of life scores. Further research is needed to study which aspects of the intervention are useful and which elements need improvement.Trial RegistrationNederlands Trial Register (NTR) 1658

Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs will become unsustainable for universal healthcare access. Moreover, early market access of new oncology medicines lacking appropriate clinical evaluation generates uncertainty over their cost-effectiveness and increases expenditure for unknown health gain. Patient-level data can complement clinical trials and generate better evidence on the effectiveness, safety and outcomes of these new medicines in routine care. This can support policy decisions including funding. Consequently, there is a need for improving datasets for establishing real-world outcomes of newly launched oncology medicines.Aim: To outline the types of available datasets for collecting patient-level data for oncology among different European countries. Additionally, to highlight concerns regarding the use and availability of such data from a health authority perspective as well as possibilities for cross-national collaboration to improve data collection and inform decision-making.Methods: A mixed methods approach was undertaken through a cross-sectional questionnaire followed-up by a focus group discussion. Participants were selected by purposive sampling to represent stakeholders across different European countries and healthcare settings. Descriptive statistics were used to analyze quantifiable questions, whilst content analysis was employed for open-ended questions.Results: 25 respondents across 18 European countries provided their insights on the types of datasets collecting oncology data, including hospital records, cancer, prescription and medicine registers. The most available is expenditure data whilst data concerning effectiveness, safety and outcomes is less available, and there are concerns with data validity. A major constraint to data collection is the lack of comprehensive registries and limited data on effectiveness, safety and outcomes of new medicines. Data ownership limits data accessibility as well as possibilities for linkage, and data collection is time-consuming, necessitating dedicated staff and better systems to facilitate the process. Cross-national collaboration is challenging but the engagement of multiple stakeholders is a key step to reach common goals through research.Conclusion: This study acts as a starting point for future research on patient-level databases for oncology across Europe. Future recommendations will require continued engagement in research, building on current initiatives and involving multiple stakeholders to establish guidelines and commitments for transparency and data sharing.

Snapshot img

Contract Research Organization Market Size 2025-2029

The contract research organization (CRO) market size is forecast to increase by USD 85.3 billion at a CAGR of 14.6% between 2024 and 2029.

The market is experiencing significant growth due to the expansion of the biopharmaceutical industry and the increasing number of clinical trials. The biopharmaceutical sector's growth is driven by the rising prevalence of chronic diseases, the ongoing research and development of new treatments, and the integration of telemedicine and gene therapy advancements. Additionally, CROs provide cost savings and efficiency to pharmaceutical and biotech companies by managing clinical trials and regulatory compliance. BioAgile Therapeutics, a leading company offers contract research organization (CRO) services such as comprehensive clinical research solutions, including medical writing, clinical data management, site management, and regulatory services tailored for pharmaceuticals and medical devices.

What will be the Size of the Contract Research Organization (CRO) Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of services essential to pharmaceutical and biotechnology companies in their quest for new drug discoveries and regulatory approvals. Key areas of focus include oncology research, pharmaceutical development, clinical trial management, regulatory affairs, pharmacovigilance, drug discovery, clinical trial design, and drug safety. CROs also provide expertise in personalized medicine, clinical data management, data analysis, biostatistics, clinical operations, medical research, and healthcare consulting. Additionally, they offer services related to healthcare technology, immunotherapy, cell therapy, precision medicine, drug delivery, clinical trial recruitment, biomarker discovery, medical device development, and healthcare analytics. CROs play a pivotal role in various phases of pharmaceutical development, from early-stage research to post-market surveillance, enabling healthcare innovation and investment in the life sciences sector.

How is this Contract Research Organization (CRO) Industry segmented?

The contract research organization (CRO) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Application

  Clinical research
  Early phase development
  Laboratory
  Regulatory consulting


End-user

  Pharmaceutical and biopharmaceutical companies
  Medical device companies
  Academic institutes


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    UK


  Asia
  Rest of World (ROW)

By Application Insights

The clinical research segment is estimated to witness significant growth during the forecast period. Contract Research Organizations (CROs) provide essential clinical research services, overseeing the strategic planning, execution, and oversight of clinical trials. Their expertise includes designing trial protocols, selecting investigative sites, and managing patient recruitment. CROs ensure regulatory compliance, implement rigorous monitoring and maintain data quality throughout the trial process. This accelerates drug development, enhancing efficiency and compliance. Research centers collaborate with CROs for tissue-based clinical research, funded by key players or governments, expanding their research and development capabilities. CROs offer services in various sectors, including pharmaceuticals, biotechnology, oncology drugs, drug development, clinical operations, oncology clinical trials, immunological disorders, regulatory affairs, biopharmaceuticals, analytical testing, respiratory disorders, healthcare, product approval, raw material testing, diabetes, target identification, data analytics, and medical devices.

Their role is crucial in the development of new treatments for cardiovascular diseases, genomic testing, cell gene therapy, and genomic testing devices. CROs also provide quality assurance, regulatory consulting, investments, mergers, productivity research services, patient population management, and clinical trial supplies.

Get a glance at the market report of share of various segments Request Free Sample

The Clinical research segment was valued at USD 31.00 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America holds a significant share due to the presence of numerous pha

The size of the Virtual Clinical Trials Industry market was valued at USD 9.52 Million in 2023 and is projected to reach USD 17.79 Million by 2032, with an expected CAGR of 9.34% during the forecast period. The virtual clinical trials sector is moving very fast because of the recognition of a more efficient and adaptable way of conducting clinical research in recent times. Virtual clinical trials use digital technologies to conduct studies from remote settings; participants can thus participate from their homes using telemedicine, mobile health apps, and wearable devices to collect data. The method has improved on patient recruitment, retention, and compliance, especially among patients who would otherwise be discouraged from participating in traditional trials. The main drivers of growth in this sector are a continued focus on patient-centric trial designs, technology advancements, as well as the COVID-19 pandemic, which previously accelerated the spread of remote trial design. Regulatory bodies have also started to embrace virtual approaches that can offer the potential for more cost-effective and efficient trials for some time now. The market includes various stakeholders, like pharma companies, CROs, and technology providers. Those players are investing in innovative solutions to streamline the processes under a trial, data management, and regulatory compliance. Geographical Areas: North America is leading in the market based on the present healthcare infrastructure and technological advancement. However, the Asian Pacific is accelerating rapidly, which gets driven by increasing investments in the clinical research area along with a rise in focus on digital health solutions. Overall, virtual clinical trials is going to continue seeing growth because that is an element of this systemic shift toward more accessible, efficient, and patient-centered approaches in clinical research. Key drivers for this market are: Growing Digitization in Healthcare Sector, Technological Advancements in Virtual Clinical Trials; Prevalence of Chronic Disease. Potential restraints include: Challenges Associated with the Virtual Clinical Trials. Notable trends are: The Oncology Segment is Expected to Occupy a Significant Share of the Market Over the Forecast Period.

The global adrenocortical carcinoma (ACC) drugs market is a niche but rapidly evolving therapeutic area characterized by a relatively small patient population but significant unmet medical needs. While precise market size figures for 2025 are unavailable in the provided data, considering a typical CAGR (Compound Annual Growth Rate) for specialized oncology drugs of 8-12% between 2019-2024 and extrapolating this for the future, the market value in 2025 could be estimated to be between $300 million and $500 million (assuming a base year value near the lower end of this range, factoring in market entry of newer drugs and their impact on growth). Key drivers include increasing ACC incidence rates, growing awareness among healthcare professionals and patients, and ongoing research and development efforts focused on novel therapeutic approaches. Current treatment options are limited and often associated with significant side effects, creating a strong impetus for innovative therapies. The market is segmented by drug type (e.g., targeted therapies, chemotherapies, immunotherapies) and application (e.g., first-line treatment, second-line treatment). Companies such as Bristol-Myers Squibb, Eli Lilly, and others are actively involved in research and development or commercialization within this field. Market restraints include the relatively low prevalence of ACC, the complexity of clinical trials in this rare cancer, and associated high development costs. The forecast period (2025-2033) suggests continued market expansion, fueled by the introduction of new and more effective therapies. Regional variations in healthcare infrastructure, access to advanced treatments, and regulatory frameworks will influence market performance. North America and Europe are expected to dominate the market initially due to better access to advanced medical treatments and higher healthcare spending. However, growth in emerging markets like Asia-Pacific is anticipated due to rising healthcare expenditure, increasing awareness, and an expanding patient population. The continued focus on personalized medicine and the development of targeted therapies tailored to specific ACC subtypes are critical aspects shaping future market dynamics. This growth will necessitate a concerted effort among pharmaceutical companies, researchers, and regulatory bodies to ensure equitable access to life-saving therapies for ACC patients globally.

The Global Immuno Oncology Assays market size was $4.5 Billion in 2021 and it is forecasted to reach $7.8 Billion by 2026. Immuno Oncology Assays Industry's Compound Annual Growth Rate will be 8.17% from 2022 to 2026. Driving Factors in the Immuno Oncology Assays Market:

Increasing incidence of cancer and rising adoption of targeted therapies

Cancer is a composite disease that evolves through multiple stages of carcinogenesis procedure compelling multiple molecular paths. With the cancer diagnosis, prognosis, and therapy numerous complications are allied. However, in consist of molecular profile every cancer differs from the others. Therefore, immuno-oncology assays have been especially significant in understanding cancer signatures and developing customized therapies. World wide the pervasiveness of cancer has risen drastically over the last some years. Cancer has become the prominent cause of death all over the world, on count over 9.6 million of the population die in 2018. More than 60% of new cancer patients occur in Asia, Africa, and South America.

Increasing research and development funding will drive the market growth

The highest investment in the fight against cancer is from research and development, specifically rigor medicine giving them personal care. Thereupon in the future, cancer treatment is likely to contain a merger of immunotherapy and individualized therapy. The outcome will be seen better in patients because of the advanced technology such as surgical and radiation in cancer management. These are some factors that boost the market growth.

Restraining Factors of Immuno Oncology Assays Market:

The high medical cost cause serious problems that may restrain the market growth

Patients have severe problems with huge medical expenses. The knockoff of affordable medicines has impacted the health of people in underdeveloped and developing countries and invested in smaller life expectancy. Immunotherapy cost $1000,000 per patient and it may increase to 8,50,000 per patient if the price of medical aid will be considered. As the outcome is due to the high cost of immuno-oncology therapy, the growth of the immuno-oncology market can get restrained.

Require high capital investment and low-cost benefit ratio

Significant capital investments are needed for the detection, expansion, and endorsement of biomarkers. Also, due to high drug abrasion in clinical trials, diagnostic producers are disclosed to serious financial challenges. To get consent for Invitro diagnostics from regulators, producers need successful completion of phase III clinical trials which rely on well endorse biomarker tests. High investments are needed to conduct clinical trials and address exact regulatory requirements, which not only impact the ability of the small companies to evolve biomarkers by critically affect the invention.

Opportunities in the Immuno Oncology Assays Market:

Approaching the market offers cost-effective opportunities

Emerging economies countries like India, China, South Korea, Brazil, and Mexico give significant growth opportunities to key players in the market. This can be associated with their low administrative boundary, in the healthcare framework, increasing patient population, and increasing healthcare expenses. The administrative policies in the Asian Pacific are more flexible and business-friendly than the policies in the developed countries. The key players in the immuno-oncology assays market focus on the approaching countries because of the rising competition in the mature market.

Current Trends in the Immuno Oncology Assays Market:

Preventing cancer is a public health challenge all over the world, with the rising number of patients in every country. With the rising pervasiveness of cancer, the claim for safe and adequate treatment is also rising promptly. As an outcome, the key players in the market are concentrating on developing and launching novel cancer therapeutics, and this trend is assumed to continue over the future period, increasing the growth of the market. However, the current trend in the global immuno-oncology assays market is the expansion of immuno-oncology assays to fight cancer. Immuno-oncology deals with the study of the development of treatment and taking leverage of the body’s immune system to fight cancer. Therefore, researchers are developing new techniques, known to be...

The global Cancer Cachexia Therapeutics market is poised for significant growth, driven by rising cancer prevalence, an aging population, and increasing awareness of cachexia as a debilitating complication. While precise market size figures are not provided, considering the involvement of major pharmaceutical players like AbbVie, Pfizer, and Merck, and the substantial investment in oncology research, a reasonable estimate for the 2025 market size could be in the range of $2.5 billion to $3 billion. This estimate assumes a moderate to high growth rate given the unmet medical need and ongoing drug development efforts. The market's Compound Annual Growth Rate (CAGR) likely falls within the range of 8-12% from 2025 to 2033, fueled by the introduction of innovative therapies and improved diagnostic tools. Key market drivers include increased research and development in targeted therapies, the growing understanding of cachexia's pathophysiology, and the increasing demand for improved quality of life among cancer patients. However, challenges such as the complexity of cachexia's etiology, high drug development costs, and regulatory hurdles could restrain market expansion. Segmentation by drug type (e.g., appetite stimulants, anabolic agents, and others) and application (specific cancer types) will further define market dynamics. The North American market is expected to maintain a dominant position due to higher healthcare expenditure and advanced medical infrastructure, while Asia-Pacific is projected to witness substantial growth driven by increasing cancer incidence and improved healthcare access. The competitive landscape features established pharmaceutical companies actively engaged in developing and commercializing cachexia treatments. Strategic alliances, mergers and acquisitions, and the introduction of novel therapies are expected to shape the market's competitive dynamics. Future growth will depend on overcoming challenges related to clinical trial design, demonstrating efficacy in diverse cancer types, and achieving regulatory approvals. Focusing on personalized medicine approaches, identifying predictive biomarkers, and developing combination therapies will be crucial for enhancing treatment effectiveness and improving patient outcomes. This focus on improving patient quality of life will drive further investment and innovation within the Cancer Cachexia Therapeutics market.

All individuals diagnosed with cancer from 2000 to 2007 were identified in the Cancer Register of Southern Sweden, but only individuals who were also identified in the Population Register of Scania were included in this cohort. Age- and gender-matched controls were identified in the Population Register of Scania. The controls were reconciled with the cancer registry in southern Sweden so that they had no prior diagnosis of cancer and with the Population Register of Scania that they were alive at time of diagnosis to the matched case. Also spouses to cancer patients were used as controls.

For each individual, healthcare costs were monitored related to the date of diagnosis. Costs for outpatient care, inpatient care, number of days in hospital and medications were included. Costs were also calculated for the controls.

Other information available about the individuals in the cohort are age, sex, domicile, type of tumor and medication.

Purpose:

To study the health cost per individual in relation to mortality and comorbidity.

Dataset includes the study controls (individuals matched by age and sex ) Also spouses to cancer patients were included in the control group.

Snapshot img

Cancer Supportive Care Market Size 2024-2028

The cancer supportive care market size is forecast to increase by USD 6.26 billion at a CAGR of 4.3% between 2023 and 2028.

The market is experiencing significant growth due to the increasing prevalence of cancer cases worldwide. This trend is driven by the rising number of individuals diagnosed with cancer each year, which necessitates the need for effective supportive care treatments. Another growth factor is the advent of biosimilars in cancer-associated treatment, which offers cost-effective alternatives to branded biologics. However, the high cost of cancer treatment remains a major challenge for patients and healthcare systems, necessitating the development of more affordable treatment options. The market is expected to continue growing as new treatments and technologies emerge to address the unmet needs of cancer patients.

What will be the Size of the Cancer Supportive Care Market During the Forecast Period?

Request Free SampleThe market encompasses a range of treatments and services aimed at alleviating the adverse effects of cancer and its treatment. Key products in this market include granulocyte colony-stimulating factors (G-CSFs) for managing treatment toxicities, antiemetics for managing chemotherapy-induced nausea and vomiting, and erythropoiesis-stimulating agents (ESAs) for addressing anemia. The market is driven by the growing prevalence of cancer, particularly In the aging and geriatric population, and the increasing focus on patient-centric care. Cancer supportive care also addresses the needs of palliative and pain care specialists, who manage symptoms and side effects for patients with advanced or metastatic diseases, such as breast, colorectal, and triple-negative breast cancer.Innovative therapies, including antibody-drug combinations, clinical trials, personalized medicine, biosimilars, and generic medications, are transforming the landscape of cancer supportive care. Hospital pharmacies and online pharmacies play crucial roles in providing access to these treatments, while healthcare administration continues to prioritize cost-effective solutions for managing the complexities of cancer treatment.

How is this Cancer Supportive Care Industry segmented and which is the largest segment?

The cancer supportive care industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Therapeutic AreaChemotherapy-induced anemiaChemotherapy-induced neutropeniaCancer painCINVOthersDistribution ChannelHospitals pharmaciesDrug stores and retail pharmaciesOnline providersGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Therapeutic Area Insights

The chemotherapy-induced anemia segment is estimated to witness significant growth during the forecast period.

Anemia, a condition characterized by insufficient healthy red blood cells or hemoglobin, is a prevalent side effect experienced by cancer patients, particularly those undergoing chemotherapy. Approximately 75% of these patients develop severe anemia, which can lead to debilitating fatigue due to inadequate oxygen supply to the organs. Cancer treatment-induced anemia is a significant concern, affecting a substantial number of patients. Other symptoms include weakness, shortness of breath, and pale skin. Cancer supportive care focuses on managing treatment toxicities, including anemia, through various interventions. Healthcare professionals, including pain care specialists, palliative care specialists, nutritionists, and pharmacists, employ various strategies to alleviate anemia's symptoms and prevent complications.These strategies include administering granulocyte colony-stimulating factors, blood transfusions, and using antiemetics to manage chemotherapy-induced nausea and vomiting. Additionally, targeted molecule therapies, such as bisphosphonates, and innovative therapies, including antibody-drug combinations and biosimilars, are increasingly used to manage anemia and other cancer-related conditions. The aging population and the increasing cancer prevalence, particularly in triple-negative breast cancer and metastatic colorectal cancer, further emphasize the importance of effective cancer supportive care.

Get a glance at the Cancer Supportive Care Industry report of share of various segments Request Free Sample

The Chemotherapy-induced anemia segment was valued at USD 6.28 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 39% to the growth of the global market during the forecast period.

Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The Contract Research Organization (CRO) Solutions market is experiencing robust growth, driven by the increasing demand for outsourced clinical research services by pharmaceutical and biotechnology companies. This surge is fueled by several factors, including the rising complexity of drug development, the need for accelerated timelines, and the cost-effectiveness of outsourcing non-core functions. The market size in 2025 is estimated at $50 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This projection reflects the continued expansion of clinical trials, particularly in emerging therapeutic areas like oncology, immunology, and cell therapy, which necessitate specialized CRO services. Key segments like early-phase development and laboratory services are expected to witness above-average growth, driven by the increasing adoption of innovative technologies and advanced analytics in drug discovery and development. Geographical expansion, particularly in developing regions like Asia-Pacific, further contributes to market expansion. Leading CROs are strategically investing in expanding their service portfolios, enhancing technological capabilities, and forging strategic partnerships to capitalize on the growing market opportunities. The competitive landscape is marked by the presence of both large multinational corporations and specialized niche players. Consolidation and acquisitions are expected to remain significant trends, as larger players seek to broaden their service offerings and geographic reach. Regulatory changes and evolving ethical considerations within the clinical research landscape present both challenges and opportunities for CROs, requiring adaptation and strategic planning to ensure sustained growth. Despite potential restraints such as pricing pressures and increasing competition, the overall outlook for the CRO market remains positive, driven by the persistent demand for efficient and cost-effective drug development solutions.

Snapshot img

Cancer Registry Software Market Size 2024-2028

The cancer registry software market size is forecast to increase by USD 97.1 million at a CAGR of 12.75% between 2023 and 2028.

The growing prevalence of cancer cases is the key driver of the cancer registry software market. CDC is a key player, specializing in providing advanced cancer registry software solutions, including Registry Plus. These systems facilitate accurate and efficient data management for healthcare organizations, enabling effective tracking, analysis, and reporting of cancer patient information as well as supporting cancer immunotherapy and cancer diagnostics. By supporting improved patient care and research outcomes, CDC's solutions are essential in addressing the increasing demand for comprehensive cancer data management. 
Additionally, data privacy and security concerns are driving the market, as healthcare organizations prioritize protecting sensitive patient information. These trends are shaping the market, which is expected to continue its growth trajectory In the coming years.

What will be the Size of the Cancer Registry Software Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the increasing incidence of cancer and the need for efficient and accurate data management In the healthcare industry. With the adoption of Electronic Health Records (EHRs) and the shift towards evidence-based medicine, cancer registry software solutions have become essential tools for medical professionals to track cancer treatment, therapeutics, and patient outcomes. 
These solutions enable the collection and analysis of data on cancer prevalence, diagnostics, and specific area-focused cancer incidence. They provide valuable insights into cancer-specific outcomes, including chemotherapy, surgery, supportive treatments, and post-endoscopic resection. Furthermore, regulatory guidance documents mandate the use of cancer registry software to ensure compliance with healthcare standards and reduce healthcare costs.
Medical professionals rely on these software solutions to improve patient care and support the ongoing research and development of new cancer treatments.

How is this Cancer Registry Software Industry segmented and which is the largest segment?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premise
  Cloud


Component

  Commercial
  Public


Geography

  North America

    Canada
    US


  Europe

    Germany
    Italy


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period. Cancer registry software plays a pivotal role in managing data related to cancer cases for government hospitals and third-party agencies. This software facilitates the collection, management, and analysis of data on cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. By identifying trends and patterns, governments and agencies can target high-risk populations, address geographic disparities, and recognize emerging cancer types. Cancer registry software enhances the quality of cancer care by enabling the evaluation of treatment practices against clinical guidelines and benchmarking outcomes against standards. The software supports seamless data integration and interoperability with healthcare systems, ensuring coordinated care for cancer patients.

Medical professionals and patients alike benefit from improved cancer care through evidence-based medicine, cancer-specific outcomes, and research institutes. Software solutions cater to various cancer types, including lung cancer, and support cancer staging, treatment, disease management, diagnostics, chemo, surgery, and supportive therapies. These solutions integrate with electronic health records (EHR), enabling secure data storage and access to essential health information. Data security and security protocols are prioritized to protect patient privacy and prevent medical identity theft. Cancer registry software supports population health management, healthcare cost containment, and chronic disease management. It aligns with healthcare quality goals and streamlines hospital workflows, making it an essential tool for oncology departments, clinics, hospitals, medical practices, pharmaceutical, biotech, and medical de

Market Overview The global Clinical Trial Imaging Service market is projected to reach $XX million by 2033, exhibiting a CAGR of XX% during the forecast period 2025-2033. The market growth is driven by the increasing prevalence of chronic diseases, the rising demand for precision medicine, and the advancements in medical imaging technologies. Key market trends include the adoption of artificial intelligence (AI) and machine learning (ML) in medical imaging, the increasing globalization of clinical trials, and the growing focus on patient-centricity. However, factors such as the high costs associated with imaging services and the regulatory challenges in clinical trials may restrain market growth. Market Segments and Key Players The market is segmented based on application (oncology, cardiovascular, neurology, etc.) and type (imaging modalities, image analysis, etc.). Regionally, the market is analyzed across North America, South America, Europe, Middle East & Africa, and Asia Pacific. Major players in the Clinical Trial Imaging Service market include Bioclinica, Parexel International Corporation, Icon, Biomedical Systems Corporation (ERT), and Biotelemetry. These companies offer a comprehensive range of imaging services to support clinical trials, including protocol design, image acquisition and analysis, and data management.

The global clinical trials outsourcing market size was valued at USD 43.1 billion in 2022 and is projected to reach USD 84.3 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. The growth of the market is attributed to the increasing prevalence of chronic diseases, rising healthcare costs, and the growing need for efficient and cost-effective clinical trials. The clinical trials outsourcing market is segmented by type into phase I, phase II, phase III, and phase IV. The phase III segment accounted for the largest share of the market in 2022 and is expected to maintain its dominance during the forecast period. The growth of this segment can be attributed to the increasing number of clinical trials being conducted in the later stages of drug development. By application, the cancer segment accounted for the largest share of the market in 2022 and is expected to continue to hold a significant share during the forecast period. The growing prevalence of cancer and the increasing investment in cancer research are contributing to the growth of this segment. North America accounted for the largest share of the clinical trials outsourcing market in 2022 and is expected to remain the dominant region during the forecast period. The presence of well-established and experienced clinical research organizations (CROs), favorable government policies, and a large number of pharmaceutical and biotechnology companies are factors contributing to the growth of the market in this region.